---
title: "Huaren Health plans to acquire equity in three pharmaceutical chain companies in Fujian and Zhejiang to advance its pharmaceutical retail business"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241261242.md"
description: "Huaren Health plans to acquire equity in three pharmaceutical chain companies in Fujian and Zhejiang for a total price of 328 million yuan, advancing its pharmaceutical retail business development. This acquisition will enhance the company's market share and brand influence in the East China region, and upon completion, it will control Yangzu Huimin, Haihua Pharmaceutical, and Tonglu Yishengtang, marking the company's transformation from a local enterprise to a regional pharmaceutical chain enterprise"
datetime: "2025-05-21T13:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241261242.md)
  - [en](https://longbridge.com/en/news/241261242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241261242.md)
---

# Huaren Health plans to acquire equity in three pharmaceutical chain companies in Fujian and Zhejiang to advance its pharmaceutical retail business

According to the Zhitong Finance APP, Huaren Health (301408.SZ) announced that in order to continuously promote the company's pharmaceutical retail business development strategy of "deepening in Anhui, focusing on East China, and radiating surrounding areas," and to enhance the company's market share and brand influence in East China, the company plans to purchase 46.01% equity of Yangzu Huimin held by Minzhehui for RMB 133 million, 46.01% equity of Haihua Pharmaceutical held by Minzhehui for RMB 125 million, and 70.01% equity of Tonglu Yishengtang held by Minzhehui for RMB 68.25975 million.

Upon completion of this transaction, the company will gain control over Yangzu Huimin and Haihua Pharmaceutical, as well as full equity of Tonglu Yishengtang, resulting in a change in the scope of the company's consolidated financial statements. After the completion of this transaction, the company's pharmaceutical retail business will have successfully established a presence in four provinces in East China: Anhui, Jiangsu, Zhejiang, and Fujian, creating growth opportunities for the sustainable and high-quality development of the company's retail business in a favorable market environment. The completion of this acquisition marks the gradual transformation of Huaren Health's pharmaceutical retail business from a local enterprise in Anhui to an influential regional pharmaceutical chain enterprise in East China

### Related Stocks

- [301408.CN](https://longbridge.com/en/quote/301408.CN.md)

## Related News & Research

- [US probing if China firms cut output of containers before pandemic, says CBS](https://longbridge.com/en/news/286944311.md)
- [US CDC OFFICIAL SAYS AMERICAN EBOLA PATIENT HAS LANDED IN GERMANY](https://longbridge.com/en/news/287104395.md)
- [Coffee Prices Rebound on Technical Short-Covering](https://longbridge.com/en/news/286941721.md)
- [Aperture AC Announces the Pricing of $90,000,000 Initial Public Offering | APUR Stock News](https://longbridge.com/en/news/287124227.md)
- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)